Elizabeth Plant has an extensive background in the cannabis industry.
Elizabeth Plant.
Greenfern Industries has announced the appointment of non-executive independent director Elizabeth Plant.
Plant is an experienced clinician and senior manager with superior skills in influencing, risk management, and in leading the implementation of change that then remains in place. She is formerly chief medical officer of Eqalis Pharmaceuticals Ltd (now Cannasouth), a position she had held for four and a half years. In this role she had been responsible for the delivery of education packages and clinical information to health professionals and consumers, as well as coordinating licences to operate through Medsafe. She had set up and worked closely with a group of senior clinicians on a clinical advisory board for the company and has produced a series of prescribing publications and education presentations.
Previously to that she was a consultant specialising in clinical pharmacy service development, medication safety, medication management, electronic medication management, quality improvement and audit, clinical change management, leadership and workforce development, cultural organisational change, and strategic development.
Plant will be an invaluable governance leader for GFI as it transitions away from a startup business to a more established medicinal cannabis and biotechnology company.
Board chair Marvin Yee said: “We are very pleased to bring in a director with such extensive background in this industry. Elizabeth is a welcome addition to developing the next phase of Greenfern as we move to commercialisation.”
The current board of directors consists of Marvin Yee, Simon McArley, Kirsten Taylor, and Dan Casey and they extended a warm welcome to Plant and look forward to having her knowledge and prior experience in the cannabis sector to bolster the current governance board.
This is supplied content and not commissioned or paid for by NBR.
